



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
May 3, 2022

Therapeutic Class	Drug Name	DURB Recommendation
Alzheimer's Agents		
	<i>Aduhelm (Intravenous) Injection</i>	NP/PA (for coverage on the PADL)
Antipsychotics		
	<i>Lybalvi (Oral) Tablet</i>	NP/PA
Uterine Disorder Treatments		
	<i>Myfembree (Oral) Tablet</i>	P/PA
Immunomodulators, Atopic Dermatitis		
	<i>Opzelura (Topical) Cream</i>	NP/PA
Growth Hormone		
	<i>Skytrofa (Subcutaneous) Injection</i>	NP/PA
Ophthalmics, Anti-Inflammatory/Immunomodulator		
	<i>Tyrvaya (Intranasal) Spray</i>	NP/PA

DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List